Review
The Use of Vaccines in Adult Patients With Renal Disease

https://doi.org/10.1053/j.ajkd.2005.08.032Get rights and content

In patients with renal disease, infection remains among the most common causes of morbidity and mortality. Alterations in the function of the immune system, as well as unique exposures of this patient population, account for the increased risk. Vaccination is an invaluable tool in preventing many infectious diseases. Unfortunately, responsiveness to vaccination in patients with renal disease can be diminished. In the present review, we examine the available evidence on the use of vaccinations in adult patients at different stages of chronic kidney disease. We address efficacy, clinical outcomes, and potential costs of individual vaccinations and provide our recommendations based on the literature reviewed. We also identify areas in which additional research is needed.

Section snippets

Hepatitis B

Hepatitis B virus (HBV) has been a public health issue in dialysis units since the advent of hemodialysis in the 1960s, and it has remained the main infectious target of vaccination in the dialysis population. HBV is transmitted by percutaneous or mucosal exposure to infectious blood or body fluids. It is relatively stable in the environment, remaining viable on environmental surfaces at room temperature for at least 7 days. Therefore, blood-contaminated surfaces such as equipment, supplies,

Streptococcus Pneumoniae

Pneumonia remains a major cause of morbidity and mortality in patients with renal disease. According to the most recent US Renal Data System (USRDS) report, rates of pneumonia during the first year of hemodialysis have increased gradually from 24.8 admissions/100 patient-years at risk in 1991 to 30.6 admissions/100 patient-years at risk in 2001.1 Slinin et al33 reported an overall pneumonia hospitalization rate of 84.4 admissions/1,000 patient-years in 14,859 prevalent hemodialysis patients. S

Influenza

Influenza epidemics have been responsible for an average of 36,000 deaths/y in the United States between 1990 and 1999.48 Patients on dialysis therapy are at greater risk for influenza-related mortality.49 Influenza vaccination is associated with decreases in influenza-related respiratory illness, physician visits in all age groups, hospitalization and death in persons at high risk, otitis media in children, and work absenteeism in adults.48 Although influenza vaccination rates in the general

Tetanus and Diphtheria

Since the introduction of vaccination with tetanus toxoid in the 1940s, tetanus has been a rare disease in the United States, with an overall incidence of 0.02 cases/100,000 population during the late 1990s.46 The majority of cases reported occurred in persons who had not completed a 3-dose primary tetanus toxoid vaccination or for whom vaccination histories were uncertain. Adults aged 60 or older are at greatest risk for tetanus and tetanus-related mortality, with an incidence of 0.03

Hepatitis A

In most industrialized countries, there are low levels of endemic hepatitis A virus (HAV) transmission. Because most of the population in these countries are susceptible to HAV infection, outbreaks occur.70 In the United States, this is becoming more apparent with the importation of food that may be tainted.70, 71

HAV causes both acute disease and asymptomatic infection, but does not cause chronic infection. It confers lifelong immunity from future HAV infection.72 Patients with chronic liver

Varicella Vaccine

Approximately 4 million varicella cases with 4,000 to 9,000 hospitalizations and 100 deaths were reported annually in the United States before the approval of varicella vaccine in 1995 (Varivax; Merck). Although less than 5% of these cases occurred in adults older than 20 years, 55% of varicella-related deaths occurred in this age group.81 The incidence of varicella infection in patients with renal disease is not clearly defined. Although varicella is not a significant contributor to morbidity

Staphylococcus Aureus Vaccine

S aureus remains a major cause of morbidity in hemodialysis patients. An annual incidence of bacteremia caused by S aureus of 3% to 4% in hemodialysis patients was reported in the early 1990s.89 Most recent USRDS data showed that adjusted septicemia rates in the first year of dialysis therapy increased from 13.96/100 patients in 1991 to 26.16/100 patients in 2001 (Fig 3), with S aureus as the most common specified organism.3 Danese et al recently showed that septicemia caused by S aureus was

Conclusion

Vaccines remain an underused tool for the prevention of infectious complications in patients with renal disease. Nephrologists frequently serve as primary care physicians for their patients and thus need to be familiar with the data for commonly used adult vaccinations. Although patients with renal disease may have an impaired immunologic response, successful vaccination of this patient population is possible and can decrease the risk for complications from vaccine-preventable diseases. Recent

References (92)

  • J. Pazik et al.

    Pneumonia in kidney allograft recipients

    Transplant Proc

    (2003)
  • M.J. Sarnak et al.

    Pulmonary infectious mortality among patients with end-stage renal disease

    Chest

    (2001)
  • J. Nikoskelainen et al.

    Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure

    Kidney Int

    (1985)
  • F.G. Cosio et al.

    Pneumococcal vaccination in patients with chronic renal disease and renal allograft recipients

    Kidney Int

    (1981)
  • W.E. Beyer et al.

    Trivalent influenza vaccine in patients on haemodialysisImpaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components

    Vaccine

    (1987)
  • E.O. Osanloo et al.

    Antibody responses to influenza vaccination in patients with chronic renal failure

    Kidney Int

    (1978)
  • N.P. Vogtlander et al.

    Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients

    Vaccine

    (2004)
  • A.E. Ahmed et al.

    Reduction in mortality associated with influenza vaccine during 1989-90 epidemic

    Lancet

    (1995)
  • D.T. Gilbertson et al.

    Influenza vaccine delivery and effectiveness in end-stage renal disease

    Kidney Int

    (2003)
  • R.A. Vilchez et al.

    Influenza virus infection in adult solid organ transplant recipients

    Am J Transplant

    (2002)
  • M. Girndt et al.

    Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure

    Am J Kidney Dis

    (1995)
  • S. Kruger et al.

    A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients

    Am J Kidney Dis

    (2001)
  • S. Gourishankar et al.

    Herpes zoster infection following solid organ transplantationIncidence, risk factors and outcomes in the current immunosuppressive era

    Am J Transplant

    (2004)
  • USRDS 2004 Annual Data Report

    (2004)
  • S.L. Furth et al.

    Immunization practices in children with renal diseaseA report of the North American Pediatric Renal Transplant Cooperative Study

    Pediatr Nephrol

    (1997)
  • Recommended adult immunization schedule—US, 10/2004-9/05

    MMWR Morb Mortal Wkly Rep

    (2004)
  • E.L. Pesanti

    Infections in patients with CRF

    Infect Dis Clin North Am

    (2001)
  • Recommendations for preventing transmission of infections among chronic HD patients

    MMWR Morb Mortal Wkly Rep

    (2001)
  • S. Ribot et al.

    Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients

    Arch Intern Med

    (1979)
  • HepatitisControl Measures for Hepatitis B in Dialysis Centers

    (1977)
  • J.I. Tokars et al.

    National surveillance of dialysis-associated diseases in the United States, 2001

    Semin Dial

    (2004)
  • Outbreaks of hepatitis B infection among HD patients—California, Nebraska, Texas, 1994

    MMWR Morb Mortal Wkly Rep

    (1996)
  • Y.J. Hutin et al.

    An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis

    Infect Control Hosp Epidemiol

    (1999)
  • D. Palmovic et al.

    Vaccination against hepatitis BResults of the analysis of 2000 population members in Croatia

    Eur J Epidemiol

    (1994)
  • C.E. Stevens et al.

    Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy

    N Engl J Med

    (1984)
  • F. Fabrizi et al.

    Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patientsA prospective randomized study with cost-effectiveness evaluation

    Nephrol Dial Transplant

    (1997)
  • G. Hess et al.

    The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients

    J Viral Hepat

    (1996)
  • J.M. Mauri et al.

    Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona

    Nephrol Dial Transplant

    (1997)
  • C.L. Cooper et al.

    CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adultsA double-blind phase I/II study

    J Clin Immunol

    (2004)
  • D. Verthelyi et al.

    CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques

    AIDS

    (2004)
  • S.K. Agarwal et al.

    Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure

    J Assoc Physicians India

    (1999)
  • E.Z. Oddone et al.

    A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients

    Health Serv Res

    (1993)
  • P. Mathurin et al.

    Impact of hepatitis B and C virus on kidney transplantation outcome

    Hepatology

    (1999)
  • I.M. Jacobson et al.

    Immunogenicity of hepatitis B vaccine in renal transplant recipients

    Transplantation

    (1985)
  • Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP)

    MMWR Morb Mortal Wkly Rep

    (1991)
  • Y. Slinin et al.

    Clinical epidemiology of pneumonia in hemodialysis patients

    J Am Soc Nephrol

    (2004)
  • Cited by (91)

    • Chinese Clinical Practice Guideline for the Management of “CKD-PeriDialysis”-the Periods Prior to and in the Early-Stage of Initial Dialysis

      2022, Kidney International Reports
      Citation Excerpt :

      1.2.1 Dialysis isolation and disinfection systems should be implemented. Disposable dialyzers are recommended but if reusable dialyzers are used, the relevant guidelines for infection control should be strictly adhered to.76,116 1.2.2 Clinicians should ensure that hemodialysis related materials have been disinfected, and there is adequate cleaning of the dialysis environment, such as the dialysis room and equipment, to avoid cross infection.

    • Cancer in dialysis and transplant patients

      2019, Kidney Transplantation - Principles and Practice
    View all citing articles on Scopus

    The data reported here have been supplied by the US Renal Data System. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government.

    Originally published online as doi:10.1053/j.ajkd.2005.08.032 on November 3, 2005.

    View full text